17,261 trials
Thrombocytopenia Associated With Chronic Liver Disease
Primary: Percentage of Participants With Platelet Count Greater Than or Equal to 50 x 10^9/L and at Least 20 x 10^9/L Increase From Baseline at Visit 4 — 9.1; 28.6; 63.6; 40.0…
HIV
Primary: Mean Percent Change From Baseline for D-dimer (ng/mL) to the Average of Weeks 8 and 12 — -10.8; -8.5 percent
Phenylketonuria
Primary: Blood Phenylalanine Concentration — 1168.8; 617.6 umol/L
Human Rabies
Primary: Percentage of Participants With Serum Rabies Virus Neutralizing Activity — 94.3; 97.1; 97.1; 100 percentage of participants — p=0.4187
Metastatic Renal Cell Carcinoma
Primary: Phase 1b: Number of Participants With Dose-limiting Toxicity (DLT) — 1; 0; 0; 0 Participants
Leukemia
Primary: Response Rate — 55.2 percentage
Actinic Keratosis
Primary: Part 1: Number of Participants Experiencing a Dose Limiting Toxicity (DLT) Based on Local Skin Responses (LSRs) — 3; 3; 6; 6 Participants
Adult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLL
Primary: Number of Patients Achieving Complete Response Within 3 Months — 1; 1; 5; 0 Participants
Phenylketonuria
Primary: Blood Phenylalanine Concentrations — 1382.7; 1336.1; 1290.5; 846.0 umol/L
Metastatic Breast Cancer
Primary: Determine Maximum Tolerated Dose of TRC105 in Combination With Capecitabine — 0; 3; 0; 3 Participants
Acute Lymphoblastic Leukemia (ALL) · Acute Myelogenous Leukemia (AML) · Myelodysplastic Syndrome (MDS)
Primary: Acute Toxicity Associated With the Infusion of NiCord — 0 Participants
Acne Vulgaris
Primary: Mean Absolute Change in Acne Lesion Counts (Inflammatory) From Baseline to Week 12 — -10.5; -11.0; -14.6; -14.5 Lesions — p=0.0006
Cystic Fibrosis
Primary: Change in Sodium Conductance by Nasal Potential Difference (NPD) — -0.70; 1.81 mV
Lymphoma
Primary: Number of Participants With Grade 3-5 Adverse Events — 6 Participants
Phenylketonuria
Primary: Blood Phenylalanine Concentration — 1482.1; 1566.0 umol/L